EMA Grants Prestige Biopharma’s PBP1510 Orphan Drug Status for Pancreatic Cancer

The European Medicines Agency’s Orphan Drug Commission has recommended that the agency grant Prestige BioPharma an Orphan Drug designation for its monoclonal antibody pancreatic cancer treatment., PBP1510.

The designation would give the Singapore-based drugmaker market exclusivity for 10 years, among other benefits. The European Commission is expected to grant Orphan Drug status within 30 days.

PBP1510 received Orphan Drug status from the FDA and the Korean Ministry of Food and Drug Safety earlier this year.